A review of the side effects of CAR T-cell therapy, including CRS, ICANS, tumor lysis syndrome, and late-onset toxicities, and management strategies.

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

"Patients who experienced CRS or ICANS had shorter duration of these events, compared with those in pivotal trials for commercial CAR-T cell products," said Calibr in a statement. The duration of ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

SAN DIEGO -- In a propensity-matched comparison of two CAR T-cell therapies ... Severe cytokine release syndrome (CRS) ...